#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Erdheim-Chester disease Infertility male Laryngeal squamous cell carcinoma Autoimmune hepatitis Raynaud's phenomenon Familial hypertriglyceridaemia Haematological malignancy Gaucher's disease type I Breast cancer metastatic Progressive supranuclear palsy Nodal marginal zone B-cell lymphoma Deafness neurosensory Hepatic cirrhosis Neurofibroma Colitis ulcerative More trials…

    Learn about Rare Diseases

    Ewing’s sarcoma recurrent – Treatment Mantle cell lymphoma Glycogen storage disease type I – Basic Information Combined immunodeficiency – Treatment Pleomorphic leiomyosarcoma – Diagnostics Alexander disease – Treatment Hairy cell leukaemia recurrent – Life with Disease Lymphatic malformation – Trials in Disease Netherton’s syndrome – Trials in Disease Angelman’s syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Buspirone Hydrochloride SODIUM DIHYDROGEN PHOSPHATE Regn9933 Urea Alx148 Recombinant Interferon Beta-1B Magnesium Oxide, Light Canagliflozin Chlorphenamine Prednisolone Sodium Phosphate Timolol Maleate ZUNIBERGENE ROCPARVOVEC Warfarin Prasterone Oxytocin Rineterkib Eight Treg Heterodimeric Interleukin-15 Myrrh Azd4831 More therapies…

    Learn about Your Condition

    Post-traumatic stress disorder Alpha-1 antitrypsin deficiency Thromboangiitis obliterans Asplenia Testicular germ cell cancer Adenovirus infection Wheezing Cerebellar ataxia Respiratory failure Small fibre neuropathy Pancreatic neoplasm Meniscus injury Hypochondroplasia Inguinal hernia Soft tissue sarcoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Malignant melanoma

  • Long-term follow-up study of fianlimab and cemiplimab combination treatment in adult patients with melanoma

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    Investigated Drugs:
    • Fianlimab
    • Cemiplimab
    Ireland

  • Study of Pembrolizumab for Patients with High-Risk Stage IIB/IIC Melanoma

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    Investigated Drugs:
    • Pembrolizumab
    France

  • Study on Nivolumab Dose Optimization for Patients with Melanoma or Renal Cell Carcinoma Showing Complete, Partial, or Stable Response

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    • Renal cell carcinoma
    Investigated Drugs:
    • Nivolumab
    The Netherlands

  • Study Comparing MK-7684A (Vibostolimab and Pembrolizumab) with Pembrolizumab for Adults and Children with High-Risk Melanoma

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    Investigated Drugs:
    • Vibostolimab
    • Pembrolizumab
    Austria Belgium France Germany Ireland Italy +3

  • A Study of Lifileucel with Cyclophosphamide, Fludarabine, and Aldesleukin for Adults with Previously Treated Advanced Melanoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    Investigated Drugs:
    • Aldesleukin
    • Lifileucel
    • Fludarabine Phosphate
    France Germany Italy Spain

  • Study of Acasunlimab Alone and Combined With Pembrolizumab in Patients With Advanced Skin Melanoma That Returned or Did Not Respond to Prior Treatment

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Acasunlimab
    • Pembrolizumab
    France Germany The Netherlands Spain
Previous Page
1 … 4 5 6 7 8 … 14
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!